Use of the Rad51 promoter for targeted anti-cancer therapy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 52, 2008, Pages 20810-20815

  Hine, Christopher M ^a,b   Seluanov, Andrei ^a   Gorbunova, Vera ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Cancer; Transcriptionally targeted therapy

Indexed keywords

DIPHTHERIA TOXIN; MESSENGER RNA; RAD51 PROTEIN;

ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; FIBROSARCOMA; HUMAN; HUMAN CELL; OPEN READING FRAME; PRIORITY JOURNAL; UTERINE CERVIX CANCER;

CELL LINE, TRANSFORMED; CELL LINE, TUMOR; DIPHTHERIA TOXIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; OPEN READING FRAMES; PEPTIDE FRAGMENTS; PROMOTER REGIONS, GENETIC; RAD51 RECOMBINASE; RNA, MESSENGER; RNA, NEOPLASM;

EID: 58549092770     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0807990106     Document Type: Article

References (48)

1. Baumann P, West SC (1998) Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem Sci 23:247-251.
2. Baumann P, Benson FE, West SC (1996) Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. Cell 87:757-766.
3. Arnaudeau C, et al. (2001) RAD51 supports spontaneous non-homologous recombination in mammalian cells, but not the corresponding process induced by topoisomerase inhibitors. Nucleic Acids Res 29:662-667.
4. Richardson C (2005) RAD51, genomic stability, and tumorigenesis. Cancer Lett 218:127-139.
5. Thacker J (2005) The RAD51 gene family, genetic instability and cancer. Cancer Lett 219:125-135.
6. Raderschall E, et al. (2002) Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res 62:219-225.
7. Maacke H, et al. (2000) DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene 19:2791-2795.
8. Xia SJ, Shammas MA, Shmookler Reis RJ (1997) Elevated recombination in immortal human cells is mediated by HsRAD51 recombinase. Mol Cell Biol 17:7151-7158.
9. Arias-Lopez C, et al. (2006) p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene. EMBO Rep 7:219-224.
10. Linke SP, et al. (2003) p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination. Cancer Res 63:2596-2605.
11. Slupianek A, et al. (2002) Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol 22:4189-4201.
12. Slupianek A, et al. (2001) BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 8:795-806.
13. Richardson C, Stark JM, Ommundsen M, Jasin M (2004) Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability. Oncogene 23:546-553.
14. Hannay JA, et al. (2007) Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. Mol Cancer Ther 6:1650-1660.
15. Collis SJ, et al. (2001) Ribozymeminigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells. Nucleic Acids Res 29:1534-1538.
16. Maacke H, et al. (2000) Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int J Cancer 88:907-913.
17. Qiao GB, et al. (2005) High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer 93:137-143.
18. Russell JS, et al. (2003) Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res 63:7377-7383.
19. Ohnishi T, et al. (1998) In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. Biochem Biophys Res Commun 245:319-324.
20. Collis SJ, Deweese TL, Jeggo PA, Parker AR (2004) The life and death of DNA-PK. Oncogene 24:949-961.
21. Hardcastle J, Kurozumi K, Chiocca EA, Kaur B (2007) Oncolytic viruses driven by tumor-specific promoters. Curr Cancer Drug Targets 7:181-189.
22. Wu L, Johnson M, Sato M (2003) Transcriptionally targeted gene therapy to detect and treat cancer. Trends Mol Med 9:421-429.
23. Lo HW, Day CP, Hung MC (2005) Cancer-specific gene therapy. Adv Genet 54:235-255.
24. Fujiwara T, Urata Y, Tanaka N (2007) Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter. Curr Cancer Drug Targets 7:191-201.
25. Abdul-Ghani R, et al. (2000) Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Mol Ther 2:539-544.
26. Koga S, et al. (2000) A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum Gene Ther 11:1397-1406.
27. Komata T, et al. (2001) Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res 61:5796-5802.
28. Kirch HC, et al. (2002) Tumor-specific activation of hTERT-derived promoters by tumor suppressive E1A-mutants involves recruitment of p300/CBP/HAT and suppression of HDAC-1 and defines a combined tumor targeting and suppression system. Oncogene 21:7991-8000.
29. Majumdar AS, et al. (2001) The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther 8:568-578.
30. Gu J, et al. (2000) Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res 60:5359-5364.
31. Nettelbeck DM, et al. (2002) Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res 62:4663-4670.
32. Latham JP, Searle PF, Mautner V, James ND (2000) Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res 60:334-341.
33. Chen JS, et al. (2004) Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther 11:740-747.
34. Yu L, et al. (2004) Midkine promoter-driven suicide gene expression and -mediated adenovirus replication produced cytotoxic effects to immortalised and tumour cells. Eur J Cancer 40:1787-1794.
35. Bilsland AE, Fletcher-Monaghan A, Keith WN (2005) Properties of a telomerase-specific Cre/Lox switch for transcriptionally targeted cancer gene therapy. Neoplasia 7:1020-1029.
36. Yamaizumi M, Mekada E, Uchida T, Okada Y (1978) One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 15:245-250.
37. Hasselbach L, et al. (2005) Characterisation of the promoter region of the human DNA-repair gene Rad51. Eur J Gynaecol Oncol 26:589-598.
38. Antoniou AC, et al. (2007) RAD51 135G->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 81:1186-1200.
39. Schmutte C, et al. (1999) Characterization of the human Rad51 genomic locus and examination of tumors with 15q14-15 loss of heterozygosity (LOH). Cancer Res 59:4564-4569.
40. Chang MP, et al. (1989) Internucleosomal DNA cleavage precedes diphtheria toxin-induced cytolysis. Evidence that cell lysis is not a simple consequence of translation inhibition. J Biol Chem 264:15261-15267.
41. Abdul-Ghani R, et al. (2000) Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Mol Ther 2:539-544.
42. Takakura M, et al. (1999) Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 59:551-557.
43. Bryan TM, et al. (1997) Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 3:1271-1274.
44. Sarntinoranont M, Iadarola MJ, Lonser RR, Morrison PF (2003) Direct interstitial infusion of NK1-targeted neurotoxin into the spinal cord: a computational model. Am J Physiol Regul Integr Comp Physiol 285:R243-254.
45. Gu J, Fang B (2003) Telomerase promoter-driven cancer gene therapy. Cancer Biol Ther 2:S64-70.
46. Kishimoto H, et al. (2006) In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat Med 12:1213-1219.
47. Wirth T, et al. (2003) A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res 63:3181-3188.
48. Pariente N, et al. (2007) A novel dual-targeted lentiviral vector leads to specific transduction of prostate cancer bone metastases in vivo after systemic administration. Mol Ther 15:1973-1981.